Assays for determining plasma kallikrein system biomarkers

Patent metadata

Field	Value
Publication number	US-11372002-B2
Application number	US-201415030811-A
Country	US
Kind code	B2
Filing date	Oct 17, 2014
Priority date	Oct 21, 2013
Publication date	Jun 28, 2022
Grant date	Jun 28, 2022

Abstract

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

First claim

What is claimed is:

1. An ex vivo activation method, comprising:
placing an activator of the plasma kallikrein (pKal) system in a plasma sample obtained from a subject to produce a mixture, wherein the activator is Factor XIIa (FXIIa);
incubating the mixture;
measuring levels of intact high molecular weight kininogen (HMWK), cleaved HMWK, or both, in the plasma sample before and after the incubation;
determining a reduction of intact HMWK in the sample after the activation and/or an elevated level of the cleaved HMWK in the sample after the activation; and
administering a therapeutic agent to the subject if the plasma sample obtained from the subject has an elevated level of the cleaved HMWK as compared to a predetermined value;
wherein the therapeutic agent is DX-2930, DX-2922, DX-88, or EpiKal-2.

2. The method of claim 1 , wherein the subject is a human patient having or at risk of having a disease associated with pKal.

3. The method of claim 2 , wherein the human patient has been subjected to a treatment of the disease.

4. The method of claim 3 , wherein the human patient has HAE and has been treated with a pKal inhibitor, which is DX-2930, DX-2922, DX-88, or EpiKal-2.

5. An ex vivo assay for determining plasma kallikrein (pKal) activity in a sample, comprising:
placing a pKal system activator and a labeled synthetic peptide substrate of pKal in a plasma sample obtained from a subject to produce a mixture, wherein the activator is Factor XIIa (FXIIa), and wherein the peptide substrate comprises a motif of PFR;
incubating the mixture;
measuring the activity of pKal in the mixture based on a cleavage rate of the substrate; and
administering a therapeutic agent to the subject if the plasma sample obtained from the subject has an elevated level of pKal activity compared to a predetermined value;
wherein the therapeutic agent is DX-2930, DX-2922, DX-88, or EpiKal-2.

6. The assay of claim 5 , wherein the labeled substrate releases a detectable signal after being cleaved by pKal and the cleavage rate of the substrate is determined based on the magnitude of the detectable signal.

7. The assay of claim 5 , wherein the subject is a human patient having or at risk of having a disease associated with pKal.

8. The assay of claim 7 , wherein the human patient has been subjected to a treatment of the disease.

9. The assay of claim 8 , further comprising evaluating the efficacy of the treatment; wherein a reduced level of pKal activity as compared to the pKal activity before the treatment or a reduced level of pKal activity over the course of the treatment indicates that the treatment is effective; and continuing the treatment on the subject, if the treatment is identified as effective.

10. The assay of claim 8 , wherein the human patient has hereditary angioedema (HAE) and has been treated with a pKal inhibitor, which is DX-2930, DX-2922, DX-88, or EpiKal-2.

11. The method of claim 2 , wherein the disease associated with pKal is hereditary angioedema (HAE).

12. The method of claim 3 , wherein the plasma sample is obtained after or during the course of the treatment.

13. The method of claim 12 , further comprising evaluating the efficacy of the treatment, and continuing the treatment on the subject who is identified as being responsive to the treatment, a reduced level of cleaved HMWK after the treatment as compared to the level of cleaved HMWK before the treatment or a reduced level of cleaved HMWK over the course of the treatment indicating that the subject is responsive to the treatment.

14. The method of claim 8 , wherein the sample is obtained after or during the course of the treatment.

15. The method of claim 7 , wherein the disease associated with pKal is hereditary angioedema (HAE).

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Sexton Daniel J
• Faucette Ryan
• Kenniston Jon A
• Conley Gregory P
• Nixon Andrew
• Tenhoor Christopher
• Adelman Burt

Classifications

• C07K16/36

  against blood coagulation factors · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2800/224

  Haemostasis or coagulation · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title

• G01N33/573

  for enzymes or isoenzymes · CPC title